Patents by Inventor Janice Au-Young

Janice Au-Young has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6057110
    Abstract: The present invention provides a polynucleotide (hhp) which identifies and encodes a novel human hyaluronidase (HHP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HHP. The invention also provides for the use of substantially purified HHP and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of HHP. Additionally, the invention provides for the use of antisense molecules to hhp in pharmaceutical compositions for treatment of diseases associated with the expression of HHP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of hhp. The present invention also relates to anti-HHP antibodies which specifically bind to HHP.
    Type: Grant
    Filed: December 17, 1998
    Date of Patent: May 2, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Phillip R. Hawkins, Jennifer L. Hillman
  • Patent number: 6045792
    Abstract: The present invention provides novel human protein kinases (HPK) and polynucleotides which identify and encode HPK. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPK. The invention also provides for pharmaceutical compositions comprising HPK or antagonists of HPK, and antibodies which specifically bind HPK. Additionally, the invention provides antisense molecules to HPK for treatment or prevention of diseases associated with abnormal expression of HPK.
    Type: Grant
    Filed: July 7, 1998
    Date of Patent: April 4, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Karl J. Guegler, Phillip R. Hawkins
  • Patent number: 6043343
    Abstract: The present invention provides novel human tumor proteins (collectively called TUPRO) and polynucleotides which identify and encode TUPRO. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding TUPRO. The invention also provides pharmaceutical compositions containing TUPRO or antagonists to TUPRO, and in the use of these compositions for the treatment of diseases associated with the expression of TUPRO. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding TUPRO for the treatment of diseases associated with the expression of TUPRO. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding TUPRO or anti-TUPRO antibodies which specifically bind to TUPRO.
    Type: Grant
    Filed: September 29, 1998
    Date of Patent: March 28, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Janice Au-Young, Surya K. Goli, Jennifer L. Hillman
  • Patent number: 6043222
    Abstract: The invention provides a two new human DnaJ-like proteins (HSPJ1 or HSPJ2) and polynucleotides which identify and encode HSPJ1 or HSPJ2. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HSPJ1 or HSPJ2.
    Type: Grant
    Filed: September 2, 1999
    Date of Patent: March 28, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Preeti Lal, Olga Bandman
  • Patent number: 6037164
    Abstract: The present invention provides a human parvulin-like protein (HPVLP) and polynucleotides which identify and encode HPVLP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPVLP and a method for producing HPVLP. The invention also provides for agonists, antibodies, or antagonists specifically binding HPVLP, and their use, in the prevention and treatment of diseases associated with expression of HPVLP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPVLP for the treatment of diseases associated with the expression of HPVLP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPVLP.
    Type: Grant
    Filed: February 14, 1997
    Date of Patent: March 14, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventor: Janice Au-Young
  • Patent number: 6034219
    Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human macrophage antigen (TMAH). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding TMAH. The invention also provides for the use of substantially purified TMAH and its agonists, antibodies, antagonists or inhibitors in pharmaceutical compositions for treatment of diseases associated with expression of TMAH. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the genomic sequence or transcripts encoding TMAH and anti-TMAH antibodies which specifically bind to TMAH.
    Type: Grant
    Filed: July 10, 1998
    Date of Patent: March 7, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jennifer L. Hillman, Janice Au-Young, Surya K. Goli
  • Patent number: 6030826
    Abstract: The present invention provides a human parvulin-like protein (HPVLP) and polynucleotides which identify and encode HPVLP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPVLP and a method for producing HPVLP. The invention also provides for agonists, antibodies, or antagonists specifically binding HPVLP, and their use, in the prevention and treatment of diseases associated with expression of HPVLP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPVLP for the treatment of diseases associated with the expression of HPVLP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPVLP.
    Type: Grant
    Filed: December 9, 1998
    Date of Patent: February 29, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventor: Janice Au-Young
  • Patent number: 6023659
    Abstract: Disclosed is a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to one or more protein function hierarchies. The hierarchies allow searches for sequences based upon a protein's biological function or molecular function. Also disclosed is a mechanism for automatically grouping new sequences into protein function hierarchies. This mechanism uses descriptive information obtained from "external hits" which are matches of stored sequences against gene sequences stored in an external database such as GenBank. The descriptive information provided with the external database is evaluated according to a specific algorithm and used to automatically group the external hits (or the sequences associated with the hits) in the categories.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: February 8, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jeffrey J. Seilhamer, Ingrid E. Akerblom, Christina M. Altus, Tod M. Klingler, Frank Russo, Janice Au-Young, Jennifer L. Hillman, Timothy J. Maslyn
  • Patent number: 6018028
    Abstract: The present invention provides polynucleotides which identify and encode novel human proteasome subunit proteins. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding PSUB. The invention also provides for the use of substantially purified PSUB, antagonists, and in pharmaceutical compositions for the treatment of diseases associated with the expression of PSUB. Additionally, the invention provides for the use of antisense molecules to PSUB in pharmaceutical compositions for treatment of diseases associated with the expression of PSUB. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding PSUB or anti-PSUB antibodies which specifically bind to PSUB.
    Type: Grant
    Filed: August 13, 1998
    Date of Patent: January 25, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Janice Au-Young, Jennifer L. Hillman, Surya K. Goli
  • Patent number: 6015788
    Abstract: The present invention provides polynucleotides which identify and encode a novel human nucleic acid binding protein (NABP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NABP. The invention also provides for the use of substantially purified NABP or its antagonists, in pharmaceutical compositions for the treatment of diseases associated with the expression of NABP. Additionally, the invention provides for the use of antisense molecules to NABP in pharmaceutical compositions for treatment of diseases associated with the expression of NABP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding NABP or anti-NABP antibodies which specifically bind to NABP.
    Type: Grant
    Filed: November 19, 1998
    Date of Patent: January 18, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Janice Au-Young, Phillip R. Hawkins, Jennifer L. Hillman
  • Patent number: 6008039
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel purinergic P.sub.U2 receptor (PNR) expressed in human placenta. The present invention also provides for antisense molecules to the nucleotide sequences which encode PNR, expression vectors for the production of purified PNR, antibodies capable of binding specifically to PNR, hybridization probes or oligonucleotides for the detection of PNR-encoding nucleotide sequences, genetically engineered host cells for the expression of PNR, and diagnostic tests based on PNR-encoding nucleic acid molecules or antibodies produced against the polypeptide PNR.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 28, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Roger Coleman, Janice Au-Young, Susan G. Stuart, Karl J. Guegler
  • Patent number: 6001598
    Abstract: The invention provides a two new human DnaJ-like proteins (HSPJ1 or HSPJ2) and polynucleotides which identify and encode HSPJ1 or HSPJ2. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HSPJ1 or HSPJ2.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: December 14, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Preeti Lal, Olga Bandman
  • Patent number: 5989883
    Abstract: The present invention provides a polynucleotide (ubcp) which identifies and encodes a novel ubiquitin-conjugating enzyme (UBCP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding UBCP. The invention also provides for the use of substantially purified UBCP and its agonists, antagonists, or inhibitors in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of UBCP. Additionally, the invention provides for the use of antisense molecules to ubcp in pharmaceutical compositions for treatment of diseases associated with the expression of UBCP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of ubcp or anti-UBCP antibodies which specifically bind to UBCP.
    Type: Grant
    Filed: November 20, 1998
    Date of Patent: November 23, 1999
    Inventors: Janice Au-Young, Surya K. Goli, Jennifer L. Hillman
  • Patent number: 5972649
    Abstract: The invention provides a human multiple endocrine neoplasia type 1 protein (MEND1) and polynucleotides which identify and encode MEND1. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of MEND1.
    Type: Grant
    Filed: May 29, 1997
    Date of Patent: October 26, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Peter A. Covitz, Y. Tom Tang, Lynn E. Murry
  • Patent number: 5969104
    Abstract: The present invention provides a polynucleotide (mctl) which identifies and encodes a novel human C-type lectin (MCTL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding MCTL. The invention also provides for the use of substantially purified MCTL and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of MCTL. Additionally, the invention provides for the use of antisense molecules to mctl in pharmaceutical compositions for treatment of diseases associated with the expression of MCTL. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of mctl. The present invention also relates to anti-MCTL antibodies which specifically bind to MCTL.
    Type: Grant
    Filed: July 10, 1998
    Date of Patent: October 19, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Benjamin Graeme Cocks, Surya K. Goli, Jennifer L. Hillman
  • Patent number: 5958731
    Abstract: The invention provides a human cell junction PDZ protein (CJPDZ) and polynucleotides which identify and encode CJPDZ. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of CJPDZ.
    Type: Grant
    Filed: September 11, 1998
    Date of Patent: September 28, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Henry Yue, Janice Au-Young, Chandra Patterson
  • Patent number: 5958750
    Abstract: The present invention provides a polynucleotide (hhp) which identifies and encodes a novel human hyaluronidase (HHP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HHP, and a method for making HHP with the host cells.
    Type: Grant
    Filed: July 3, 1996
    Date of Patent: September 28, 1999
    Assignee: Inctye Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Phillip R. Hawkins, Jennifer L. Hillman
  • Patent number: 5955303
    Abstract: The present invention provides a human chemokine receptor-like, protein (NHCR) and polynucleotides which identify and encode NHCR. The invention also provides expression vectors, host cells, agonists, antibodies, and antagonists. The invention also provides methods for treating disorders associated with expression of NHCR.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: September 21, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Janice Au-Young, Karl J. Guegler, Muzong Cheng
  • Patent number: 5953727
    Abstract: Disclosed is a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to association with one or more projects for obtaining full-length biomolecular sequences from shorter sequences. The relational database has sequence records containing information identifying one or more projects to which each of the sequence records belong. Each project groups together one or more biomolecular sequences generated during work to obtain a full-length gene sequence from a shorter sequence. The computer system has a user interface allowing a user to selectively view information regarding one or more projects. The relational database also provides interfaces and methods for accessing and manipulating and analyzing project-based information.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: September 14, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Timothy J. Maslyn, Janice Au-Young, Jennifer L. Hillman, Harold Hibbert, Ingrid E. Akerblom, Rachel J. Cheng, Yuanhua T. Tang
  • Patent number: 5952177
    Abstract: The invention provides a human cytosolic isocitrate dehydrogenase (HCID) and polynucleotides which identify and encode HCID. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating disorders associated with expression of HCID.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: September 14, 1999
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Olga Bandman, Preeti Lal, Neil C. Corley, Janice Au-Young